All In Biotech

Drug Trial Radar · NCT00128297

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Randomized, Multicentric Phase IV Clinical Trial for the Administration of Pamidronate in Breast Cancer Patients With Bone Metastases

Last checked: Nov 20, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Oct 18, 2000

Primary completion

Jun 4, 2004

Study completion Jun 4, 2004

Sponsor

Lead sponsor
Spanish Breast Cancer Research GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis
First posted
Aug 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study objective is to evaluate the differences, in terms of first occurrence of a skeletal event, in patients with breast cancer and symptomatic bone metastases, when pamidronate is administered during 2 years, or when it is administered during 6 months, followed by a six month rest period, and again a 6 month treatment period.

Conditions

  • Breast Cancer
  • Neoplasm Metastasis

Interventions

  • PamidronateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pamidronate efficacy to prevent first skeletal event: time until the appearance of the first skeletal eventTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Spanish Breast Cancer Research Group (GEICAM)

    San Sebastián de los Reyes, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.